Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hartmann, Karin
HARBOR, NCT04910685 / 2020-005173-28: () Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis	Recruiting	2/3	463	Europe, US, RoW	Elenestinib, BLU-263, Placebo	Blueprint Medicines Corporation	Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis	06/28	06/28
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II	Completed	N/A	140	Europe, RoW		Shire, Takeda Development Center Americas, Inc.	Hereditary Angioedema (HAE)	09/24	09/24